Vitamin B 12 in the treatment of chronic hepatitis C

The effect of vitamin B12 supplementation to the standard therapeutic regimen on sustained viral response in genotype 1 chronic HCV infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201508064226N3

Enrollment

Registered

2015-09-20

Start date

2015-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C. Chronic viral hepatitis C

Interventions

Intervention 1: Intervention group: Monthly injection of 1000microgr vitamin b12 produced by Osveh company for 12 months totally. Intervention 2: Control group: Control group will only receive standa

Treatment - Drugs

Intervention group: Monthly injection of 1000microgr vitamin b12 produced by Osveh company for 12 months totally.

Control group: Control group will only receive standard treatment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Exclusion criteria: age 70 year, previous treatment with interferon and ribavirin, concomitant causes of liver disease, such as hepatitis B virus infection, autoimmunity and alcohol abuse (>40 g/day for men and >20 g/day for women), HIV infection, hepatocellular carcinoma, decompensated cirrhosis, severe concurrent disease, contraindications to treatment. Inclusion criteria: age between 18 to70 years, Lack of concomitant causes of liver disease, such as hepatitis B virus infection, autoimmunity and alcohol abuse (>40 g/day for men and >20 g/day for women), Lack of HIV infection, Lack of hepatocellular carcinoma, Lack of decompensated cirrhosis, Lack of severe concurrent disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sustained Virologic Response. Timepoint: 6 months after treatment course. Method of measurement: copy of virus in ml of serum.	—

Secondary

Measure	Time frame
Serum viral load. Timepoint: baseline-3months-6months- end of treatment. Method of measurement: Copy of virus per mililiter.;Liver enzymes. Timepoint: baseline-3months-6months- end of treatment- 6 months after treatment course. Method of measurement: miligram per deciliter of serum.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholam Reza Sivandzadeh

Gastroenterohepatology research center, Shiraz University of Medical Sciences

ghsivand@sums.ac.ir+98 71 3647 3236

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026